<!DOCTYPE html>
<html lang="en">
<head>        <meta charset="utf-8">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">    <link
        rel="stylesheet"
        href="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/css/bootstrap.min.css"
        integrity="sha384-Gn5384xqQ1aoWXA+058RXPxPg6fy4IWvTNh0E263XmFcJlSAwiGgFAW/dAiS6JXm"
        crossorigin="anonymous"
    />
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/c3/0.6.12/c3.min.css"/>
    <style>
        h2 {
            margin-top: 35px;
        }

        html, body {
            height: 100%;
        }

        body {
            display: flex;
            flex-flow: column;
        }

        .footer {
            margin-top: auto;
            padding-top: 1em;
            background-color: #f5f5f5;
        }
    </style>    <title>ZIRN_TRETINOIN_RESPONSE_UP</title></head>

<body>
<nav class="navbar navbar-expand-lg navbar-light bg-light">
    <span class="navbar-brand">
        Molecular Signatures Database
    </span>
</nav>

<div class="container" style="margin-top: 50px; margin-bottom: 50px">
<div class="card">
        <div class="card-header">
            ZIRN_TRETINOIN_RESPONSE_UP
        </div>
        <div class="card-body">
                <p>Wilms tumor is one of the most frequent neoplasias in children. Our previous microarray screening in a large series of Wilms tumors revealed several candidate genes that are deregulated in advanced tumors and are part of the retinoic acid signaling pathway. To investigate whether retinoic acid could be employed as a novel therapeutic agent in these tumors, we treated cultured Wilms tumor cells with different concentrations of all-trans retinoic acid (ATRA) and assessed gene expression changes by real-time RT-PCR as well as microarray analysis. Several genes like RARRES1, RARRES3, CTGF, CKS2, CCNA2, IGFBP3, UBE2C, CCL2 or ITM2B that were previously found to be deregulated in advanced tumors exhibited opposite expression changes after ATRA treatment. In addition to enhanced retinoid signaling, the transforming growth factor-beta (TGFbeta) pathway was strongly activated by ATRA treatment of Wilms tumor cells. Both the retinoic acid and the TGFbeta pathway mediate inhibition of cell growth. These findings represent the first molecular evidence of a potential benefit from ATRA treatment in Wilms tumors.</p>
            <dl>
                <dt>Local Unique Identifier</dt>
                <dd><a href="https://bioregistry.io/msigdb:M581">M581</a>
                </dd>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            in taxon (<code>RO:0002162</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/NCBITaxon:9606">NCBITaxon:9606</a></li>
                        </ol>
                    </dt>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            has part (<code>BFO:0000051</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/ncbigene:10769">ncbigene:10769</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:22795">ncbigene:22795</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:81671">ncbigene:81671</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:79875">ncbigene:79875</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:9249">ncbigene:9249</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:54407">ncbigene:54407</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:9590">ncbigene:9590</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:6578">ncbigene:6578</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:257000">ncbigene:257000</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:5916">ncbigene:5916</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:6347">ncbigene:6347</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:5343">ncbigene:5343</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:389136">ncbigene:389136</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:5329">ncbigene:5329</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3910">ncbigene:3910</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:5915">ncbigene:5915</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:6886">ncbigene:6886</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:124152">ncbigene:124152</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:5920">ncbigene:5920</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:1490">ncbigene:1490</a></li>
                        </ol>
                    </dt>
            </dl>
            <span class="badge badge-warning">Term generation via PyOBO is currently under construction</span>
            <blockquote>
                Term(reference=Reference(prefix=&#39;msigdb&#39;, identifier=&#39;M581&#39;, name=&#39;ZIRN_TRETINOIN_RESPONSE_UP&#39;), definition=&#39;Wilms tumor is one of the most frequent neoplasias in children. Our previous microarray screening in a large series of Wilms tumors revealed several candidate genes that are deregulated in advanced tumors and are part of the retinoic acid signaling pathway. To investigate whether retinoic acid could be employed as a novel therapeutic agent in these tumors, we treated cultured Wilms tumor cells with different concentrations of all-trans retinoic acid (ATRA) and assessed gene expression changes by real-time RT-PCR as well as microarray analysis. Several genes like RARRES1, RARRES3, CTGF, CKS2, CCNA2, IGFBP3, UBE2C, CCL2 or ITM2B that were previously found to be deregulated in advanced tumors exhibited opposite expression changes after ATRA treatment. In addition to enhanced retinoid signaling, the transforming growth factor-beta (TGFbeta) pathway was strongly activated by ATRA treatment of Wilms tumor cells. Both the retinoic acid and the TGFbeta pathway mediate inhibition of cell growth. These findings represent the first molecular evidence of a potential benefit from ATRA treatment in Wilms tumors.&#39;, provenance=[Reference(prefix=&#39;pubmed&#39;, identifier=&#39;15897880&#39;, name=None)], relationships=defaultdict(&lt;class &#39;list&#39;&gt;, {TypeDef(reference=Reference(prefix=&#39;RO&#39;, identifier=&#39;0002162&#39;, name=&#39;in taxon&#39;), comment=None, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=None, holds_over_chain=None): [Reference(prefix=&#39;NCBITaxon&#39;, identifier=&#39;9606&#39;, name=&#39;Homo sapiens&#39;)], TypeDef(reference=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000051&#39;, name=&#39;has part&#39;), comment=&#39;Inverse of part_of&#39;, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000050&#39;, name=&#39;part of&#39;), holds_over_chain=None): [Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;10769&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;22795&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;81671&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;79875&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;9249&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;54407&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;9590&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;6578&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;257000&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;5916&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;6347&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;5343&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;389136&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;5329&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3910&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;5915&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;6886&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;124152&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;5920&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;1490&#39;, name=None)]}), properties=defaultdict(&lt;class &#39;list&#39;&gt;, {&#39;category_code&#39;: [&#39;C2&#39;], &#39;sub_category_code&#39;: [&#39;CGP&#39;], &#39;contributor&#39;: [&#39;Leona Saunders&#39;], &#39;exact_source&#39;: [&#39;Table 1: Fold change in MS427 &gt; 0&#39;]}), parents=[], synonyms=[], xrefs=[], alt_ids=[], namespace=None, is_obsolete=False)
            </blockquote>
        </div>
    </div></div>

<footer class="footer">
    <p class="small text-center text-muted">
        Generated with PyOBO
    </p>
</footer>

<script src="https://code.jquery.com/jquery-3.2.1.slim.min.js"
        integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN"
        crossorigin="anonymous"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/js/bootstrap.min.js"
        integrity="sha384-JZR6Spejh4U02d8jOt6vLEHfe/JQGiRRSQQxSfFWpi1MquVdAyjUar5+76PVCmYl"
        crossorigin="anonymous"></script></body>
</html>